DK3448364T3 - Målretning af det iboende immunsystem med henblik på at frembringe langvarig tolerance og at opløse akkumulering af makrofager ved aterosklerose - Google Patents
Målretning af det iboende immunsystem med henblik på at frembringe langvarig tolerance og at opløse akkumulering af makrofager ved aterosklerose Download PDFInfo
- Publication number
- DK3448364T3 DK3448364T3 DK17790646.8T DK17790646T DK3448364T3 DK 3448364 T3 DK3448364 T3 DK 3448364T3 DK 17790646 T DK17790646 T DK 17790646T DK 3448364 T3 DK3448364 T3 DK 3448364T3
- Authority
- DK
- Denmark
- Prior art keywords
- macrophages
- atherosclerosis
- targeting
- dissolve
- accumulation
- Prior art date
Links
- 201000001320 Atherosclerosis Diseases 0.000 title 1
- 238000009825 accumulation Methods 0.000 title 1
- 210000000987 immune system Anatomy 0.000 title 1
- 230000007774 longterm Effects 0.000 title 1
- 210000002540 macrophage Anatomy 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
- A61K51/1224—Lipoprotein vesicles, e.g. HDL and LDL proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1275—Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662329676P | 2016-04-29 | 2016-04-29 | |
| PCT/US2017/030444 WO2017190145A1 (en) | 2016-04-29 | 2017-05-01 | Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3448364T3 true DK3448364T3 (da) | 2022-05-02 |
Family
ID=60161161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17790646.8T DK3448364T3 (da) | 2016-04-29 | 2017-05-01 | Målretning af det iboende immunsystem med henblik på at frembringe langvarig tolerance og at opløse akkumulering af makrofager ved aterosklerose |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20190290593A1 (https=) |
| EP (2) | EP4014967A1 (https=) |
| JP (2) | JP7262100B2 (https=) |
| CN (2) | CN109640959B (https=) |
| AU (3) | AU2017257189B2 (https=) |
| CA (1) | CA3021645A1 (https=) |
| DK (1) | DK3448364T3 (https=) |
| ES (1) | ES2913073T3 (https=) |
| PL (1) | PL3448364T3 (https=) |
| PT (1) | PT3448364T (https=) |
| WO (1) | WO2017190145A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109640959B (zh) * | 2016-04-29 | 2023-03-17 | 西奈山伊坎医学院 | 靶向先天免疫系统以诱导长期耐受性及解决动脉粥样硬化中的巨噬细胞累积 |
| AU2018370237B2 (en) * | 2017-11-20 | 2024-10-17 | Icahn School Of Medicine At Mount Sinai | Inhibiting trained immunity with a therapeutic nanobilogic composition |
| US20230001010A1 (en) * | 2019-07-19 | 2023-01-05 | The Regents Of The University Of Michigan | Compositions and methods for treating autoimmune disorders |
| US20220409702A1 (en) * | 2019-11-22 | 2022-12-29 | The Research Foundation For The State University Of New York | Compositions and methods for use in type 1 diabetes |
| CN111494320A (zh) * | 2020-04-24 | 2020-08-07 | 上海交通大学医学院附属仁济医院 | 一种载糖皮质激素的纳米载体及其制备和应用 |
| KR20230030644A (ko) * | 2020-06-29 | 2023-03-06 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 항-단백질 단일-도메인 항체 및 이를 포함하는 폴리펩타이드 |
| AU2022239614A1 (en) * | 2021-03-19 | 2023-10-12 | Icahn School Of Medicine At Mount Sinai | Compounds for regulating trained immunity, and their methods of use |
| CN114788835B (zh) * | 2022-04-07 | 2024-01-23 | 中山大学附属第三医院 | Foxp3阳性巨噬细胞在制备治疗急性脑梗死药物中的应用 |
| WO2025240555A1 (en) * | 2024-05-14 | 2025-11-20 | The Regents Of The University Of Michigan | Nanoparticle compositions associated with celastrol and/or rapamycin |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1138436A (en) | 1978-02-24 | 1982-12-28 | Gerhard Baschang | Process for the manufacture of novel antigens |
| JPS5528933A (en) | 1978-08-21 | 1980-02-29 | Dai Ichi Seiyaku Co Ltd | Muramyldipeptide dimer |
| JPS5618996A (en) | 1979-06-21 | 1981-02-23 | Dai Ichi Seiyaku Co Ltd | Muramyldipeptide derivative |
| FI75578C (fi) | 1979-07-25 | 1988-07-11 | Ciba Geigy Ag | Analogifoerfarande foer framstaellning av farmakologiskt verkande lipofila fosfatidylmuramylpeptider. |
| JPS58172399A (ja) | 1982-04-05 | 1983-10-11 | Dai Ichi Seiyaku Co Ltd | ムラミルトリペプチド誘導体 |
| EP0102319B1 (de) | 1982-07-23 | 1987-08-19 | Ciba-Geigy Ag | Verwendung von Muramylpeptiden oder deren Analogen zur Prophylaxe und Therapie von Virusinfektionen |
| FI852105L (fi) | 1984-05-29 | 1985-11-30 | Ciba Geigy Ag | Acylerade sockerderivat, foerfarande foer deras framstaellning och deras anvaendning. |
| JPS6157597A (ja) | 1984-08-29 | 1986-03-24 | Toshiyuki Hamaoka | ムラミルペプチド活性エステル誘導体 |
| EP0192609A3 (de) | 1985-02-20 | 1988-04-27 | Ciba-Geigy Ag | Acylierte Hexosederivate und Verfahren zu ihrer Herstellung |
| EP0192611A3 (de) | 1985-02-20 | 1988-05-11 | Ciba-Geigy Ag | Acylierte Hexosederivate und Verfahren zu ihrer Herstellung |
| US4640911A (en) | 1985-05-29 | 1987-02-03 | Ciba-Geigy Corporation | Acylated sugar derivatives, processes for their manufacture, and their use |
| US5540931A (en) * | 1989-03-03 | 1996-07-30 | Charles W. Hewitt | Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| US5506204A (en) | 1991-11-19 | 1996-04-09 | Peptech (Uk) Limited | Muramyl compounds for treatment of septic shock |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| US5349060A (en) | 1993-01-07 | 1994-09-20 | American Home Products Corporation | Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| GB9320820D0 (en) | 1993-10-08 | 1993-12-01 | Biokine Tech Ltd | Compounds for medicinal use |
| SK78196A3 (en) | 1993-12-17 | 1997-02-05 | Sandoz Ag | Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| GB9413935D0 (en) | 1994-07-11 | 1994-08-31 | Peptech Uk Ltd | Use of maramyl peptide compounds |
| GB9419011D0 (en) | 1994-09-21 | 1994-11-09 | Peptech Uk Ltd | Use of muramyl peptide compounds |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5985890A (en) | 1995-06-09 | 1999-11-16 | Novartis Ag | Rapamycin derivatives |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| GB9618673D0 (en) | 1996-09-06 | 1996-10-16 | Peptech Uk Ltd | The use of muramyl peptides |
| CA2407897A1 (en) | 2000-05-05 | 2001-11-15 | Cytos Biotechnology Ag | Molecular antigen arrays and vaccines |
| CA2319928A1 (en) | 2000-09-18 | 2002-03-18 | Vasogen Ireland Limited | Apoptosis-mimicking synthetic entities and use thereof in medical treatments |
| GB0025414D0 (en) | 2000-10-16 | 2000-11-29 | Consejo Superior Investigacion | Nanoparticles |
| US7592008B2 (en) | 2000-11-20 | 2009-09-22 | The Board Of Trustees Of The University Of Illinois, A Body Corporate And Politic Of The State Of Illinois | Membrane scaffold proteins |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| AU2004224761A1 (en) | 2003-03-26 | 2004-10-07 | Cytos Biotechnology Ag | HIV-peptide-carrier-conjugates |
| MXPA06006738A (es) | 2003-12-19 | 2006-08-31 | Univ North Carolina | Metodos para fabricar micro- y nano-estructuras aisladas utilizando litografia suave o de impresion. |
| JP4224115B2 (ja) | 2004-04-14 | 2009-02-12 | ワイス | ラパマイシン４２−エステル誘導体の位置特異的合成 |
| KR100560102B1 (ko) | 2004-06-25 | 2006-03-13 | 한국생명공학연구원 | 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제 |
| WO2006080951A2 (en) | 2004-07-01 | 2006-08-03 | Yale University | Targeted and high density drug loaded polymeric materials |
| CA2587411A1 (en) | 2004-11-17 | 2006-05-26 | Protiva Biotherapeutics, Inc. | Sirna silencing of apolipoprotein b |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| JP2009504192A (ja) | 2005-08-19 | 2009-02-05 | サイリーン ファーマシューティカルズ インコーポレーティッド | ヒトリボソームＤＮＡ（ｒＤＮＡ）およびリボソームＲＮＡ（ｒＲＮＡ）核酸ならびにそれらの使用 |
| CA2683063A1 (en) | 2007-04-09 | 2008-10-16 | Chimeros, Inc. | Self-assembling nanoparticle drug delivery system |
| CN101096386A (zh) | 2007-06-05 | 2008-01-02 | 复旦大学 | Dectin-1与热休克蛋白Hsp60聚合物及其编码核酸和应用 |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| US7928100B2 (en) | 2007-10-05 | 2011-04-19 | Cylene Pharmaceuticals, Inc. | Quinolone analogs and methods related thereto |
| JP2011500569A (ja) | 2007-10-12 | 2011-01-06 | マサチューセッツ インスティテュート オブ テクノロジー | ワクチンナノテクノロジー |
| EP2217221B1 (en) | 2007-10-17 | 2018-06-27 | Korea Advanced Institute of Science and Technology | Ldl-like cationic nanoparticles for deliverying nucleic acid gene, method for preparing thereof and method for deliverying nucleic acid gene using the same |
| CN105903029A (zh) | 2007-12-12 | 2016-08-31 | 大学健康网络 | 高密度脂蛋白样肽磷脂支架（“hpps”）纳米颗粒 |
| WO2009106999A2 (en) | 2008-02-28 | 2009-09-03 | Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts | Hollow nanoparticles and uses thereof |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| US8268796B2 (en) | 2008-06-27 | 2012-09-18 | Children's Hospital & Research Center At Oakland | Lipophilic nucleic acid delivery vehicle and methods of use thereof |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| CN102264364B (zh) | 2008-10-22 | 2014-06-18 | 康奈尔大学 | 一种多环化合物及其相关方法 |
| US20120015899A1 (en) | 2008-10-25 | 2012-01-19 | Plant Bioscience, Limited | Modified plant virus particles and uses therefor |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ | Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用 |
| US9051567B2 (en) | 2009-06-15 | 2015-06-09 | Tekmira Pharmaceuticals Corporation | Methods for increasing efficacy of lipid formulated siRNA |
| US10525152B2 (en) | 2009-10-09 | 2020-01-07 | Signablok, Inc. | Methods and compositions for targeted imaging |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| WO2011082400A2 (en) | 2010-01-04 | 2011-07-07 | President And Fellows Of Harvard College | Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
| WO2011159877A2 (en) | 2010-06-18 | 2011-12-22 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| EP2620156B1 (en) | 2010-08-23 | 2019-03-27 | Kang Stem Biotech Co., Ltd. | Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing stem cells treated with nod2 agonist or cultured product thereof |
| KR101253399B1 (ko) * | 2010-10-26 | 2013-04-11 | 영남대학교 산학협력단 | 아포지단백질 ａ－ｉ 및 그 변이체를 포함한 재조합 고밀도지단백질을 이용한 라파마이신 제형 |
| US20140086839A1 (en) | 2011-03-17 | 2014-03-27 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Quinolone analogs for treating autoimmune diseases |
| CN102178954B (zh) | 2011-04-25 | 2014-05-28 | 中国药科大学 | 具有血管壁靶向和逆向转运胆固醇功能的重组高密度脂蛋白载药系统及其应用 |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| WO2013192310A1 (en) * | 2012-06-19 | 2013-12-27 | Massachusetts Institute Of Technology | Mass production and size control of nanoparticles through controlled microvortices |
| EP2703384A1 (en) | 2012-08-27 | 2014-03-05 | Ludwig-Maximilians-Universität München | Inhibitors of CD40-TRAF6 interaction |
| IL292510A (en) | 2013-11-05 | 2022-06-01 | Cognate Bioservices Inc | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
| CN103589699B (zh) | 2013-11-05 | 2015-05-13 | 江南大学 | 一种可溶性淀粉底物特异性提高的环糊精糖基转移酶 |
| ES2754207T3 (es) | 2013-11-28 | 2020-04-16 | Tel Hashomer Medical Res Infrastructure & Services Ltd | Inhibidores de la ARN polimerasa I y usos de los mismos |
| PL4023249T3 (pl) | 2014-04-23 | 2025-03-10 | Modernatx, Inc. | Szczepionki z kwasem nukleinowym |
| WO2016019333A1 (en) | 2014-07-31 | 2016-02-04 | Kinemed, Inc. | The effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties |
| US10610564B2 (en) | 2015-02-26 | 2020-04-07 | Stc.Unm | IRGM and precision autophagy controls for antimicrobial and inflammatory disease states and methods of detection of autophagy |
| US11642419B2 (en) | 2015-03-25 | 2023-05-09 | The Regents Of The University Of Michigan | Compositions and methods for treating cardiovascular related disorders |
| JP2018516847A (ja) | 2015-03-25 | 2018-06-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 生体高分子薬を送達するための組成物及び方法 |
| WO2016155809A1 (en) | 2015-03-31 | 2016-10-06 | Biontech Rna Pharmaceuticals Gmbh | Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell |
| ES2819473T3 (es) | 2015-04-20 | 2021-04-16 | Memorial Sloan Kettering Cancer Center | Obtención de imágenes de macrófagos asociados a tumor |
| WO2016172615A1 (en) | 2015-04-24 | 2016-10-27 | University Of Delaware | Synthetic n-acetyl-muramic acid derivatives and uses thereof |
| US10995140B2 (en) | 2015-06-05 | 2021-05-04 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | GM-CSF/CD40L vaccine and checkpoint inhibitor combination therapy |
| BR112018000217A2 (pt) | 2015-07-15 | 2018-09-04 | Celator Pharmaceuticals Inc | sistemas de distribuição de nanopartículas aperfeiçoados |
| US20180221289A1 (en) | 2015-08-06 | 2018-08-09 | Autotelic Llc | Phospholipid-cholesteryl ester nanoformulations and related methods |
| CA3008837A1 (en) * | 2015-12-18 | 2017-06-22 | Northwestern University | Nitric oxide releasing high density lipoprotein-like nanoparticles (no hdl nps) |
| US20190008918A1 (en) | 2016-03-08 | 2019-01-10 | Bioxcel Corporation | Immunomodulation therapies for cancer |
| CN109640959B (zh) | 2016-04-29 | 2023-03-17 | 西奈山伊坎医学院 | 靶向先天免疫系统以诱导长期耐受性及解决动脉粥样硬化中的巨噬细胞累积 |
| EP3464270B1 (en) | 2016-05-24 | 2022-02-23 | Genentech, Inc. | Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer |
| WO2018071549A1 (en) | 2016-10-11 | 2018-04-19 | New York University | Nanoparticles and uses thereof |
| CN106831614B (zh) | 2017-01-09 | 2020-07-28 | 清华大学 | 取代的苯并二氮杂环类化合物及其制备方法和用途 |
| WO2018187515A1 (en) | 2017-04-04 | 2018-10-11 | Avidea Technologies, Inc. | Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response |
| AU2018370237B2 (en) | 2017-11-20 | 2024-10-17 | Icahn School Of Medicine At Mount Sinai | Inhibiting trained immunity with a therapeutic nanobilogic composition |
| EP3713548A4 (en) | 2017-11-21 | 2021-06-23 | Icahn School of Medicine at Mount Sinai | Promoting trained immunity with therapeutic nanobiologic compositions |
| KR102198900B1 (ko) | 2019-05-10 | 2021-01-07 | 서강대학교 산학협력단 | 질병 치료용 나노입자 복합체 및 이의 제조방법 |
| AU2022239614A1 (en) | 2021-03-19 | 2023-10-12 | Icahn School Of Medicine At Mount Sinai | Compounds for regulating trained immunity, and their methods of use |
| JP2025511149A (ja) | 2022-03-31 | 2025-04-15 | アイカーン スクール オブ メディスン アット マウント サイナイ | 免疫調節のためのスフィンゴ脂質をロードしたナノ生物製剤 |
-
2017
- 2017-05-01 CN CN201780041257.3A patent/CN109640959B/zh active Active
- 2017-05-01 ES ES17790646T patent/ES2913073T3/es active Active
- 2017-05-01 EP EP22155443.9A patent/EP4014967A1/en active Pending
- 2017-05-01 JP JP2018556339A patent/JP7262100B2/ja active Active
- 2017-05-01 DK DK17790646.8T patent/DK3448364T3/da active
- 2017-05-01 PT PT177906468T patent/PT3448364T/pt unknown
- 2017-05-01 EP EP17790646.8A patent/EP3448364B1/en active Active
- 2017-05-01 PL PL17790646.8T patent/PL3448364T3/pl unknown
- 2017-05-01 AU AU2017257189A patent/AU2017257189B2/en active Active
- 2017-05-01 US US16/097,013 patent/US20190290593A1/en not_active Abandoned
- 2017-05-01 CA CA3021645A patent/CA3021645A1/en active Pending
- 2017-05-01 WO PCT/US2017/030444 patent/WO2017190145A1/en not_active Ceased
- 2017-05-01 CN CN202310107087.1A patent/CN116077439A/zh active Pending
-
2022
- 2022-06-30 AU AU2022204675A patent/AU2022204675B2/en active Active
-
2023
- 2023-03-14 US US18/121,527 patent/US12377054B2/en active Active
- 2023-04-04 JP JP2023060872A patent/JP2023085437A/ja active Pending
-
2025
- 2025-08-14 AU AU2025217324A patent/AU2025217324A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4014967A1 (en) | 2022-06-22 |
| US20190290593A1 (en) | 2019-09-26 |
| CA3021645A1 (en) | 2017-11-02 |
| JP2019515926A (ja) | 2019-06-13 |
| AU2017257189A1 (en) | 2018-11-15 |
| CN109640959A (zh) | 2019-04-16 |
| AU2025217324A1 (en) | 2025-09-04 |
| US20230218537A1 (en) | 2023-07-13 |
| CN109640959B (zh) | 2023-03-17 |
| AU2017257189B2 (en) | 2022-03-31 |
| WO2017190145A1 (en) | 2017-11-02 |
| PL3448364T3 (pl) | 2022-08-16 |
| PT3448364T (pt) | 2022-05-04 |
| EP3448364A4 (en) | 2019-12-25 |
| JP2023085437A (ja) | 2023-06-20 |
| JP7262100B2 (ja) | 2023-04-21 |
| US12377054B2 (en) | 2025-08-05 |
| ES2913073T3 (es) | 2022-05-31 |
| EP3448364A1 (en) | 2019-03-06 |
| AU2022204675B2 (en) | 2025-09-04 |
| AU2022204675A1 (en) | 2022-09-15 |
| CN116077439A (zh) | 2023-05-09 |
| EP3448364B1 (en) | 2022-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3448364T3 (da) | Målretning af det iboende immunsystem med henblik på at frembringe langvarig tolerance og at opløse akkumulering af makrofager ved aterosklerose | |
| GB201906670D0 (en) | Systems and methods to detect stress allergy and thermal asymmetry | |
| DK2958588T3 (da) | Kombination af vaccination og hæmning af PD-1-reaktionsvejen | |
| DK2949924T3 (da) | Systemer og fremgangsmåder til omkalibrering af vindmøllenacelleposition og vindretningsestimering | |
| DK3067575T3 (da) | Skrue til undgåelse af revner og grater | |
| DK2909808T3 (da) | Forbedringer i og i forbindelse med behandling af undersøgelsesdata om en undervandsscene | |
| DK2971167T3 (da) | Sammensætninger og fremgangsmåder til targeting af nucleinsyre med nucleinsyrer | |
| DK3174976T3 (da) | Fremgangsmåder og systemer til forarbejdning af partikler | |
| DK3104717T3 (da) | Saccharosereduktion og generering af uopløselige fibre i juice | |
| DK3510049T5 (da) | Varianter af sur alfa-glucosidase og anvendelser deraf | |
| DK3034868T3 (da) | Systemer og metoder til øgning af vindturbinekraftoutput | |
| DK3292873T3 (da) | Kombination af vaccination og hæmning af PD-1-vejen | |
| IL246094B (en) | Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs | |
| EP3341387A4 (en) | SIALYL TRANSFERASE INHIBITORS AND USES THEREOF | |
| DK3380313T3 (da) | Forbedringer vedrørende fremstillingen af vindmøllevinger | |
| EP3546765A4 (en) | BRIDLE CONNECTING STRUCTURE AND BRACKET | |
| DK3394778T3 (da) | Fremgangsmåde og system til at forbedre sikkerheden af en transaktion | |
| SI3112542T1 (sl) | Naprava in postopek za toplotno ločitev betoniranih delov zgradbe | |
| DK3673489T3 (da) | Fremgangsmåder og systemer til beregning af forskelle i fri energi ved anvendelse af et alkymistisk tilbageholdelsespotentiale | |
| IL259202A (en) | Modified immune cells and uses thereof | |
| DK3163069T3 (da) | Vindturbine-montagesystem og tilhørende fremgangsmåde | |
| DK3042669T3 (da) | Antitumormiddel og forstærker af antitumorvirkning | |
| SI3370733T1 (sl) | Postopek za aktivacijo CD40 in blokada imunske nadzorne točke | |
| PL3337506T3 (pl) | Kombinacje i ich zastosowania | |
| DK3507453T3 (da) | Forbedringer af eller i forbindelse med geotermiske kraftværker |